formulations against e coli atcc 25922  (ATCC)

Journal: Pharmaceutics

Article Title: Mucosal Adhesive Chitosan Nanogel Formulations of Antibiotics and Adjuvants (Terpenoids, Flavonoids, etc.) and Their Potential for the Treatment of Infectious Diseases of the Gastrointestinal Tract.

doi: 10.3390/pharmaceutics15092353

Figure Lengend Snippet: Figure 3. The dependences of E. coli and Lactobacillus colony-forming units on the incubation time of cells with antibacterial drugs. For E. coli: C(LF) = 1 µg/mL, C(MN) = 0.1 mg/mL, C(zephirol) = 0.1 mg/mL, C(EG) = 0.1 mg/mL. For Lactobacillus: C(LF) = 10 µg/mL, C(MN) = 1 mg/mL, C(zephirol) = 0.1 mg/mL, C(EG) = 1 mg/mL. LB medium (pH 7.2). 37 ◦C.

Article Snippet: The experimental steps necessary for the development of such a composition are given below: (1) obtaining inclusion complexes of antibiotics and adjuvants with MCD, as well as the inclusion of these complexes in nanogels of chitosan, cross-linked or not with genipin; (2) primary screening of antibacterial activity of formulations against E. coli ATCC 25922 (as a screening model of pathogenic bacteria) and Lactobacilli (as a model of normal microbiome) to optimize the composition of the drug; (3) studying the effect of the most promising preparations in a long-term experiment; (4) the study of the mechanisms of antibacterial action of nanogels using FTIR spectroscopy, which provides information about the structural components of cells, as well as the study of the physicochemical basis of the nanogels formation; (5) study of antioxidant and mucoadhesive properties of drugcontaining chitosan nanogels, which are important for preventing bacterial infection and stimulating early healing; (6) studies of the activity of the effect of drugs on sturgeon fish; (7) summarizing the activity of drug formulations in vitro and in vivo and discussing the potential applicability for the treatment of infectious diseases of the gastrointestinal tract.

Techniques: Incubation

Journal: Pharmaceutics

Article Title: Mucosal Adhesive Chitosan Nanogel Formulations of Antibiotics and Adjuvants (Terpenoids, Flavonoids, etc.) and Their Potential for the Treatment of Infectious Diseases of the Gastrointestinal Tract.

doi: 10.3390/pharmaceutics15092353

Figure Lengend Snippet: Figure 4. (a) FTIR spectra of suspension of E. coli cells (109 CFU) after a day of incubation with drug formulations in Chit5 particles. C(LF) = 1 µg/mL, C(MN, MM, SHA) = 0.1 mg/mL, C (other substances) = 1 mg/mL. LB medium (pH 7.2). (b) FTIR spectra of suspension of E. coli cells (109 CFU) during incubation (online) with linalool–MCD in Chit5 particles. 37 ◦C. (c,d) Flow cytometry dia- grams of E. coli cells incubated with FITC-labeled Chit5–genipin nanogel 15 min (CFITC = 1 µg/mL). (e,f) Flow cytometry diagrams of E. coli cells (control). Green indicates a population with a high inten- sity of FITC fluorescence. SSC—side scattering, FSC—front scattering, FITC—fluorescence channel.

Article Snippet: The experimental steps necessary for the development of such a composition are given below: (1) obtaining inclusion complexes of antibiotics and adjuvants with MCD, as well as the inclusion of these complexes in nanogels of chitosan, cross-linked or not with genipin; (2) primary screening of antibacterial activity of formulations against E. coli ATCC 25922 (as a screening model of pathogenic bacteria) and Lactobacilli (as a model of normal microbiome) to optimize the composition of the drug; (3) studying the effect of the most promising preparations in a long-term experiment; (4) the study of the mechanisms of antibacterial action of nanogels using FTIR spectroscopy, which provides information about the structural components of cells, as well as the study of the physicochemical basis of the nanogels formation; (5) study of antioxidant and mucoadhesive properties of drugcontaining chitosan nanogels, which are important for preventing bacterial infection and stimulating early healing; (6) studies of the activity of the effect of drugs on sturgeon fish; (7) summarizing the activity of drug formulations in vitro and in vivo and discussing the potential applicability for the treatment of infectious diseases of the gastrointestinal tract.

Techniques: Suspension, Incubation, Flow Cytometry, Labeling, Control